Literature DB >> 20503435

Aboard transthyretin: From transport to cleavage.

Márcia A Liz1, Fernando M Mar, Filipa Franquinho, Mónica M Sousa.   

Abstract

Transthyretin (TTR) is a plasma and cerebrospinal fluid protein mainly recognized as the transporter of thyroxine (T(4)) and retinol. Mutated TTR leads to familial amyloid polyneuropathy, a neurodegenerative disorder characterized by TTR amyloid deposition particularly in peripheral nerves. Beside its transport activities, TTR is a cryptic protease and participates in the biology of the nervous system. Several studies have been directed at finding new ligands of TTR to further explore the biology of the protein. From the identified ligands, some were in fact TTR protease substrates. In this review, we will discuss the existent information concerning TTR ligands/substrates.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20503435     DOI: 10.1002/iub.340

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  15 in total

Review 1.  Signaling by vitamin A and retinol-binding protein in regulation of insulin responses and lipid homeostasis.

Authors:  Daniel C Berry; Noa Noy
Journal:  Biochim Biophys Acta       Date:  2011-07-12

Review 2.  Vitamin A homeostasis and cardiometabolic disease in humans: lost in translation?

Authors:  Aprajita S Yadav; Nina Isoherranen; Katya B Rubinow
Journal:  J Mol Endocrinol       Date:  2022-08-22       Impact factor: 4.869

Review 3.  The role of transthyretin in cell biology: impact on human pathophysiology.

Authors:  Joana Magalhães; Márcia Almeida Liz; Jessica Eira
Journal:  Cell Mol Life Sci       Date:  2021-07-23       Impact factor: 9.261

4.  Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy.

Authors:  Maike F Dohrn; Christoph Röcken; Jan L De Bleecker; Jean-Jacques Martin; Matthias Vorgerd; Peter Y Van den Bergh; Andreas Ferbert; Katrin Hinderhofer; J Michael Schröder; Joachim Weis; Jörg B Schulz; Kristl G Claeys
Journal:  J Neurol       Date:  2013-10-08       Impact factor: 4.849

5.  The serum protein transthyretin as a platform for dimerization and tetramerization of antibodies and Fab fragments to enable target clustering.

Authors:  Kenneth W Walker; Ian N Foltz; Tina Wang; Hossein Salimi-Moosavi; Julie M Bailis; Fei Lee; Phillip An; Stephen Smith; Richele Bruno; Zhulun Wang
Journal:  J Biol Chem       Date:  2020-06-09       Impact factor: 5.157

6.  Redox-proteomics of the effects of homogentisic acid in an in vitro human serum model of alkaptonuric ochronosis.

Authors:  Daniela Braconi; Claretta Bianchini; Giulia Bernardini; Marcella Laschi; Lia Millucci; Adriano Spreafico; Annalisa Santucci
Journal:  J Inherit Metab Dis       Date:  2011-08-27       Impact factor: 4.982

7.  Obesity Drives Delayed Infarct Expansion, Inflammation, and Distinct Gene Networks in a Mouse Stroke Model.

Authors:  Todd C Peterson; Kendra J Lechtenberg; Brian D Piening; Tawaun A Lucas; Eric Wei; Hassan Chaib; Alexa K Dowdell; Michael Snyder; Marion S Buckwalter
Journal:  Transl Stroke Res       Date:  2020-06-25       Impact factor: 6.829

8.  A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis.

Authors:  Teresa Coelho; David Adams; Isabel Conceição; Márcia Waddington-Cruz; Hartmut H Schmidt; Juan Buades; Josep Campistol; John L Berk; Michael Polydefkis; Jing Jing Wang; Jihong Chen; Marianne T Sweetser; Jared Gollob; Ole B Suhr
Journal:  Orphanet J Rare Dis       Date:  2020-07-08       Impact factor: 4.123

9.  Sulfated metabolites of polychlorinated biphenyls are high-affinity ligands for the thyroid hormone transport protein transthyretin.

Authors:  Fabian A Grimm; Hans-Joachim Lehmler; Xianran He; Larry W Robertson; Michael W Duffel
Journal:  Environ Health Perspect       Date:  2013-04-12       Impact factor: 9.031

10.  Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis.

Authors:  Jessica E Sutherland; Julia L Hettinger; Amy Chan; Jason Gilbert; Garvin L Warner; Wendell P Davis
Journal:  Nucleic Acid Ther       Date:  2019-12-10       Impact factor: 5.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.